Insights
Search Results
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Client Highlights
7.30.25
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
The Wilson Sonsini team advising ImmunityBio includes:
Corporate
Patents and Innovations
For more information, please see ImmunityBio’s press release.
Alerts
5.01.25
Method of Treatment Claim’s Limiting Preamble Must Satisfy the Written Description Requirement
On March 13, 2025, the U.S. Court of Appeals for the Federal Circuit issued a decision in the case of In Re: Xencor, Inc.1 In this Appeal from the Appeals Review Panel of the Patent Trial and Appeal Board (ARP), with regard to U.S. Application No. 16/803,690 (’690 application), the court held that the preamble of the method of treatment claims at issue is limiting, and thus requires sufficient written description under 35 U.S.C. §112.
Client Highlights
4.16.25
Wilson Sonsini Advises ABL Bio on Worldwide Licensing Agreement with GSK
On April 6, 2025, ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B. The agreement aims to develop multiple programs for novel targets across therapeutic modalities to address significant unmet medical needs of patients suffering from neurodegenerative conditions. Wilson Sonsini Goodrich & Rosati is advising ABL Bio on the transaction.
Client Highlights
10.18.24
Wilson Sonsini Advises Goldman Sachs Alternatives on Patent Matters Related to Series B Investment in Triveni Bio
On October 2, 2024, Triveni Bio, a biotech company advancing novel antibody treatments for immunological and inflammatory disorders, announced the completion of a $115 million Series B funding round led by Goldman Sachs Alternatives with significant participation from additional new investors Fidelity Management & Research Company and Deep Track Capital, and existing investors. Wilson Sonsini Goodrich & Rosati advised Goldman Sachs Alternatives on patent matters related to the transaction.
Client Highlights
10.11.24
Firm Advises MARAbio Systems on IP Matters Related to $19 Million Series A
On October 8, 2024, MARAbio Systems, Inc., a precision immunology company whose mission is to detect, treat, and prevent Maternal Autoantibody Related Autism, announced that it has closed $19 million in Series A financing. The round, which was led by investment management firm MAK Capital One, LLC, is open to new investors through year-end 2024. Wilson Sonsini Goodrich & Rosati advised MARAbio on intellectual property matters related to the transaction.
Client Highlights
1.03.24
Wilson Sonsini Advises ImmunityBio on $320 Million Investment
On January 2, 2024, ImmunityBio, Inc., a clinical-stage immunotherapy company announced an up to $320 million royalty financing and equity investment in the company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023. The additional capital provides significant financial resources for ImmunityBio to accelerate its commercialization efforts in anticipation of a potential regulatory approval, as well as to expand its pipeline within the broader urological cancer space. The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors. Wilson Sonsini Goodrich & Rosati represented ImmunityBio in the transaction.
Client Highlights
4.17.23
Firm Advises on IP and Patent Matters for Merck’s $10.8 Billion Acquisition of Prometheus
On April 16, 2023, pharmaceutical company Merck announced the $10.8 billion acquisition of clinical-stage biotechnology company Prometheus in a deal that will boost Merck’s presence in immunology. Wilson Sonsini Goodrich & Rosati advised Prometheus on IP and patent matters related to the transaction.
Client Highlights
10.19.22
Wilson Sonsini Advises Zymeworks on Exclusive Licensing Agreement with Jazz Pharmaceuticals
On October 19 2022, Zymeworks BC Inc. and Jazz Pharmaceuticals Ireland Ltd. announced that they entered into an exclusive license agreement to develop and commercialize zanidatamab. Under that arrangement, Jazz will receive an exclusive license from Zymeworks to develop and commercialize zanidatamab in the United States, Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene, Ltd.
Client Highlights
4.22.22
Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb
On April 21, 2022, Octant, a next-generation, data-driven therapeutics company developing programmable biology and chemistry to build precision medicines for complex diseases, announced an $80 million Series B financing round that was led by Catalio Capital Management and included participation from Bristol Myers Squibb and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and Fifty Years. Octant also announced it has established a Deep Mutational Scanning (DMS) biopharma partnership with Bristol Myers Squibb, and has appointed biotech industry veteran Dean “Rick” Artis as its first chief scientific officer and renowned scientist Feng Zhang to its scientific advisory board. Wilson Sonsini has advised Octant since its inception and represented Octant in the transactions.
Client Highlights
1.13.22
Wilson Sonsini Advises ABL Bio on Global Collaboration, License Agreement with SANOFI
On January 11, 2022, ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier (BBB) penetration. Under the terms of the agreement, ABL will receive $75 million in upfront payments. In addition, ABL is eligible to receive up to $985 million based on the achievement of predefined development, regulatory and commercialization milestones, including $45 million in near-term milestones. ABL is also eligible to receive royalties on net sales if the product from the collaboration is commercialized. The transaction will become effective after customary closing conditions are met, such as the HSR clearance. SANOFI will receive worldwide exclusive development and commercialization rights to ABL301. Meanwhile, ABL will lead the preclinical development and Phase 1 clinical trial of ABL301. Thereafter, SANOFI will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide.
Client Highlights
12.27.21
Wilson Sonsini Advises Sorriso on Patent Matters Related to $31 Million Series A
On December 22, 2021, Sorriso Pharmaceuticals, a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn's disease and ulcerative colitis, announced the company has closed on a $31 million Series A financing. The round was co-led by New Enterprise Associates (NEA) and Arix Bioscience plc. The new funding will be used to advance its pipeline of novel oral antibodies to address unmet needs in immune-mediated diseases.